What laboratory tests should be ordered to evaluate low serum phosphate?

Laboratory Evaluation for Hypophosphatemia

When evaluating low serum phosphate, immediately order a comprehensive metabolic bone panel including serum phosphate, calcium, creatinine, bicarbonate, 25(OH) vitamin D, 1,25(OH)₂ vitamin D, PTH, alkaline phosphatase (bone-specific in adults), and intact FGF23 if available, along with spot urine for phosphate, calcium, amino acids, glucose, low-molecular-weight proteins, and creatinine to calculate TmP/GFR and distinguish between renal phosphate wasting, inadequate intake, and FGF23-mediated disorders. 1, 2

Essential Serum Tests

• Serum phosphate confirms hypophosphatemia (defined as <2.5 mg/dL or 0.8 mmol/L) using age-related reference ranges, as levels in infants may appear normal within the first 3-4 months despite underlying disease. 1, 2, 3

• Serum calcium is the critical discriminant for categorizing etiology: elevated calcium suggests primary hyperparathyroidism, low calcium indicates secondary hyperparathyroidism or vitamin D deficiency, and normal calcium points toward primary renal phosphate wasting disorders. 1, 2, 3

• Creatinine with eGFR must be obtained because chronic kidney disease with secondary hyperparathyroidism frequently causes isolated alkaline phosphatase elevation and hypophosphatemia, and is required for TmP/GFR calculation. 1, 4, 2

• Serum bicarbonate excludes metabolic acidosis as a cause of non-selective tubular wasting. 1

• 25(OH) vitamin D is essential to exclude vitamin D deficiency, a common cause of hypophosphatemia with secondary hyperparathyroidism. 1, 2

• 1,25(OH)₂ vitamin D is typically low or inappropriately normal in renal phosphate wasting disorders, helping distinguish FGF23-mediated from non-FGF23-mediated causes. 1, 2

• Parathyroid hormone (PTH) differentiates PTH-mediated from non-PTH-mediated hypophosphatemia; levels are typically at the upper normal range or slightly elevated in X-linked hypophosphatemia, whereas they are frankly elevated in primary hyperparathyroidism. 1, 2

• Alkaline phosphatase (total or bone-specific) is elevated in active rickets in children or osteomalacia in adults; bone-specific ALP is preferred in adults to exclude hepatobiliary sources. 1, 2

Essential Urine Tests

• Spot urine phosphate, calcium, and creatinine should be obtained simultaneously with serum tests to calculate TmP/GFR (tubular maximum reabsorption of phosphate per GFR) and urinary calcium:creatinine ratio. 1, 2

• TmP/GFR calculation confirms renal phosphate wasting when fractional phosphate excretion exceeds 15% in the presence of hypophosphatemia; the formula is TmP/GFR = Pp – (Up × Pcr / Ucr), where all values must be in the same units. 1, 2, 3

• Urinary calcium:creatinine ratio helps distinguish between FGF23-mediated disorders (which typically have normal or low urinary calcium) and hereditary hypophosphatemic rickets with hypercalciuria; age-specific upper limits are: <1 year: 2.2 mol/mol, 1-3 years: 1.4,3-5 years: 1.1,5-7 years: 0.8,7-18 years: 0.7, >18 years: 0.57. 1

• 24-hour urine collection (in adults) for calcium and phosphate provides more accurate assessment than spot urine, with upper normal limit of 24-hour urinary calcium excretion being 0.1 mmol (4 mg) per kg body weight. 1

Tests to Exclude Fanconi Syndrome

• Urine amino acids, glucose, and low-molecular-weight proteins must be evaluated to rule out non-selective renal tubular phosphate wasting (Fanconi syndrome), which includes conditions like cystinosis, Dent disease, and other proximal tubular disorders. 1, 2

• Urine bicarbonate and uric acid losses should also be assessed to exclude Fanconi syndrome, as these disorders cause proximal renal tubular wasting that is not restricted to phosphate alone. 1, 2

Advanced Diagnostic Tests

• Intact FGF23 levels should be measured when available, particularly in patients with negative family history, as non-suppressed or elevated FGF23 in the setting of hypophosphatemia indicates FGF23-mediated disorders including X-linked hypophosphatemia, tumor-induced osteomalacia, autosomal hypophosphatemic rickets, or acquired causes like intravenous iron therapy (ferric carboxymaltose causing "6H-syndrome"). 1, 2

• FGF23 interpretation requires clinical context: even "low-normal" intact FGF23 levels (>27 pg/ml using Immutopics assay) suggest FGF23 excess in the setting of concomitant hypophosphatemia, as FGF23 should be suppressed when phosphate is low; however, results are influenced by the type of assay used (Immutopics vs. Kainos). 1

• Genetic testing (PHEX gene analysis for X-linked hypophosphatemia, or broader panels including DMP1, ENPP1, FGF23, CLCN5, SLC34A3) confirms the diagnosis when feasible and should be pursued if molecular analysis is available. 1, 5

Critical Timing and Pitfalls

• FGF23 measurement timing is crucial—obtain it before initiating phosphate or vitamin D therapy for most accurate interpretation, as treatment influences FGF23 levels. 2

• TmP/GFR can be falsely low in patients with insufficient phosphate intake or impaired intestinal absorption until serum phosphate is restored to normal, potentially leading to misdiagnosis of renal phosphate wasting. 2

• Consider medication-induced causes: intravenous iron (especially ferric carboxymaltose or iron isomaltoside) can cause severe FGF23-mediated hypophosphatemia ("6H-syndrome"), and alcohol-induced FGF23 syndrome is a recently recognized entity where alcohol directly stimulates FGF23 production. 1, 2

• Exclude acquired causes systematically: tumor-induced osteomalacia (especially in adults with new-onset hypophosphatemia), ectopic FGF23 syndrome in advanced malignancies (prostate, lung cancer), and primary hyperparathyroidism must be ruled out before attributing hypophosphatemia to genetic causes. 1